RxDoctor Payments Data

Katarina Allman, MD

Family Medicine · Huntsville, ALNPI 1619186632

Payments from drug & device makers

$2,046in general payments, 2019–2025

Across 93 payments — averaging $22.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$508
  • Novo Nordisk$486
  • Pfizer$155
  • Abbott$153
  • Merck$135
  • Novartis$116
  • plus $493 from 16 others

What the payments were for

  • Food & beverage$2,046100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,046 in reported general payments places this provider in the 65th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$87,397
Medicare patients
247
Services billed
1,054

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide28$45,213
JardianceEmpagliflozin34$42,617
OzempicSemaglutide27$31,427
Tresiba Flextouch U-200Insulin Degludec17$9,365
Rosuvastatin Calcium228$3,783
Atorvastatin Calcium196$1,991
Azelastine Hcl54$1,824
Levothyroxine Sodium152$1,622
Fluticasone Propionate98$1,315
Losartan Potassium118$1,295
Ezetimibe32$777
Amlodipine Besylate132$683
Metformin Hcl ErMetformin Hcl69$603
Lisinopril92$596
Allopurinol49$596

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$111$45,21328 claims
Boehringer IngelheimJardiance$21$42,61734 claims
Novo NordiskOzempic$486$31,42727 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Huntsville

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →